Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × anlotinib × 1 year × Clear all

Sponsor

Conditions

Small Cell Lung Carcinoma 6 Carcinoma, Non-Small-Cell Lung 5 Thyroid Neoplasms 3 Sarcoma 3 Pancreatic Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Whole-Brain Radiotherapy 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Platinum-resistant Ovarian Cancer (PROC) 1 Lung Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Extensive Stage Lung Small Cell Cancer 1 Craniopharyngioma 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Bevacizumab 59 atezolizumab 51 durvalumab 37 lenvatinib 35 pembrolizumab 33 Nivolumab 28 tremelimumab 23 Magnetic Resonance Spectroscopy 18 Specimen Handling 16 Sorafenib 16 Ipilimumab 13 tislelizumab 12 regorafenib 12 cabozantinib 12 apatinib 11 Radiosurgery 11 Immune Checkpoint Inhibitors 11 sintilimab 10 camrelizumab 9 Blood Specimen Collection 9 Radiotherapy 8 Immunoglobulin G 7 Cyclophosphamide 7 X-Rays 6 Hepatectomy 6 Disulfides 6 donafenib 5 Surgical Procedures, Operative 5 Fluorouracil 5 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡